Healthy Plasma

In Stock Samples

Lot # Condition Volume Race/Ethnicity Age Gender Country of Collection Medications Vials Price Action
80607 Normal (Healthy) 1.0 ML Caucasian 28 Male United States
No medications
14 $132.00
80707 Normal (Healthy) 1.0 ML Caucasian 45 Female United States 21 $132.00
80707 Normal (Healthy) 1.0 ML Caucasian 45 Female United States 1 $132.00
80607 Normal (Healthy) 1.0 ML Caucasian 28 Male United States
No medications
1 $132.00
80631 Normal (Healthy) 1.0 ML Caucasian 37 Male United States
Vitamin B Fluoxetine Bupropion Minoxidil Fluoxetine Raloxifene Estradiol injections from patches 25mg of Seroquel most nights
12 $132.00
80635 Normal (Healthy) 1.0 ML Caucasian 29 Male United States
Fish Oil/QD Vitamin D/QD Vitamin K2/QD Vitamin B12/QD
20 $132.00
80827 Normal (Healthy) 1.0 ML Hispanic/Latino 30 Female United States
Albuterol Inhaler PRN
15 $132.00
80667 Normal (Healthy) 1.0 ML Caucasian 26 Female United States
Take prebiotics/magnesium
25 $132.00
80827 Normal (Healthy) 1.0 ML Hispanic/Latino 30 Female United States
Albuterol Inhaler PRN
1 $132.00
80690 Normal (Healthy) 1.0 ML Caucasian 47 Male United States
Anastrozole 1mg once weekly (anti estrogen- TRT) Bupropion Hcl 150mg QD Escitalopram 10mg QD
11 $132.00

Healthy Human Plasma for Control and Baseline Research

Healthy Plasma is collected from IRB-consented, clinically screened healthy donors and processed within one day of collection to preserve key analytes such as cytokines, proteins, and metabolites. It supports research into inflammatory pathways, immune profiling, and biomarker discovery as matched control material. Anticoagulant type and aliquot volume are configured per project and reported per lot. Bulk plasma is available.

Why Plasma from Healthy Donors

Plasma is the fluid fraction of anticoagulated blood, separated by centrifugation without allowing the blood to clot. That distinction from serum is not cosmetic; it determines which analytes survive and which assays the specimen is fit for.

  • Because coagulation is prevented, fibrinogen and the clotting factors remain intact, making plasma the required matrix for coagulation and fibrinolysis research.
  • No clot forms, so platelets are not activated during processing and platelet-derived mediators are not released into the fluid — a major source of artefact when serum is used for cytokine and growth factor measurement.
  • Plasma is the conventional matrix for circulating cell-free nucleic acid and extracellular vesicle research, where cellular lysis during clotting would contaminate the analyte of interest.
  • Anticoagulant choice is part of the experimental design: EDTA chelates divalent cations and is standard for nucleic acid work, citrate is used for coagulation testing, and heparin is used where downstream enzymatic activity must be preserved. Specifying the tube up front avoids an unusable specimen.
  • Healthy plasma defines the baseline against which a disease-state signal is measured; without an identically collected and processed control arm, apparent biomarker differences may reflect pre-analytical handling rather than biology.
  • Because our healthy and disease-state collections run under the same protocols and processing windows, pre-analytical variables are held constant across the comparison.

Donor Stratification Available

  • Age band and sex assigned at birth, for demographic matching to a disease cohort
  • Race and ethnicity
  • Body mass index and smoking status where captured
  • Medication-free donors, or donors on defined medication classes
  • Blood type and infectious disease screening results, including viral serostatus where documented
  • Anticoagulant type, where inventory permits
  • Cohorts demographically matched to a specific disease-state collection available on request

Product Features

  • Research Use Only (RUO)
  • Plasma collected from clinically screened healthy donors
  • Processed within one day of collection
  • IRB-approved protocols and informed consent
  • Anticoagulant type specified at order where inventory permits
  • Custom aliquot volumes available upon request
  • Volumes and lot-specific processing details reported per lot

De-identified Donor Data

  • Verified healthy status following clinical screening
  • Demographic data: age, sex assigned at birth, race/ethnicity
  • Donor-reported medications and allergies
  • Additional demographic and screening metadata available on request

Applications

  • Matched control arms for disease-state biomarker discovery and validation
  • Cytokine, chemokine, and inflammation profiling
  • Proteomic and metabolomic baseline characterisation
  • Coagulation and fibrinolysis research with citrate collection
  • Circulating cell-free nucleic acid and extracellular vesicle method development
  • Immunoassay development, calibration, and matrix effect testing
  • Reference range and normal distribution establishment for candidate analytes
  • Controls for therapeutic candidate screening and pharmacokinetic method validation

Other Healthy Donor Specimen Types

Compliance and Quality Assurance

  • IRB-approved and HIPAA-compliant protocols
  • Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
  • Documentation support available for regulatory review

Ordering & Customization

Healthy plasma is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse other donor cohorts and collection formats, visit our human plasma page.

Protocols & Documentation

  • Plasma Isolation

    Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

Plasma

Frequently Asked Questions

×

Ask a Question

Need a custom Plasma cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information